Double-crossed.

This basic science research reveals how MEK- and RAF-targeted therapies for melanoma can induce, not only resistance to said targeted therapy, but also cross-resistance to immune checkpoint inhibition, suggesting another item should be added in the pro-column of first-line immunotherapy. | Haas, Nat Cancer 2021